The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

Provided herein are compounds according to formula (I): ##STR00001## Provided herein is also a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, and a method for providing anesthesia in a subject by administering such a pharmaceutical composition.

Provided herein are compounds according to formula (I): ##STR00001## Provided herein is also a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, and a method for providing anesthesia in a subject by administering such a pharmaceutical composition.

N.sup.2-phosphinyl amidine compounds, N.sup.2-phosphinyl amidinates, N.sup.2-phosphinyl amidine metal salt complexes, N.sup.2-phosphinyl amidinate metal salt complexes are described. Methods for making N.sup.2-phosphinyl amidine compounds, N.sup.2-phosphinyl amidinates, N.sup.2-phosphinyl amidine metal salt complexes, and N.sup.2-phosphinyl amidinate metal salt complexes are also disclosed. Catalyst systems utilizing the N.sup.2-phosphinyl amidine metal salt complexes and N.sup.2-phosphinyl amidinate metal salt complexes are also disclosed along with the use of the N.sup.2-phosphinyl amidine compounds, N.sup.2-phosphinyl amidinates, N.sup.2-phosphinyl amidine metal salt complexes, and N.sup.2-phosphinyl amidinate metal salt complexes for the oligomerization and/or polymerization of olefins.

N.sup.2-phosphinyl amidine compounds, N.sup.2-phosphinyl amidinates, N.sup.2-phosphinyl amidine metal salt complexes, N.sup.2-phosphinyl amidinate metal salt complexes are described. Methods for making N.sup.2-phosphinyl amidine compounds, N.sup.2-phosphinyl amidinates, N.sup.2-phosphinyl amidine metal salt complexes, and N.sup.2-phosphinyl amidinate metal salt complexes are also disclosed. Catalyst systems utilizing the N.sup.2-phosphinyl amidine metal salt complexes and N.sup.2-phosphinyl amidinate metal salt complexes are also disclosed along with the use of the N.sup.2-phosphinyl amidine compounds, N.sup.2-phosphinyl amidinates, N.sup.2-phosphinyl amidine metal salt complexes, and N.sup.2-phosphinyl amidinate metal salt complexes for the oligomerization and/or polymerization of olefins.

The application discloses pharmaceutical compounds of formula I useful for treating CNS diseases wherein m, s, R.sup.1 R.sup.5, R.sup.6 and R.sup.7 are as defined herein.

##STR00001##

The application discloses pharmaceutical compounds of formula I useful for treating CNS diseases wherein m, s, R.sup.1 R.sup.5, R.sup.6 and R.sup.7 are as defined herein.

##STR00001##

This invention relates to novel compositions comprising regioselectively substituted cellulose esters. One aspect of the invention relates to processes for preparing regioselectively substituted cellulose esters from cellulose dissolved in ionic liquids. Another aspect of the invention relates to the utility of regioselectively substituted cellulose esters in applications such as protective and compensation films for liquid crystalline displays.

Compounds of the formula I: ##STR00001##
or pharmaceutically acceptable salts thereof,
wherein m, p, q, Ar, R.sup.1 and R.sup.2 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.